Cargando…

Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases

Interstitial lung diseases (ILD) are a heterogeneous group of illnesses of known and unknown aetiology. Differential diagnosis among the three disorders is often challenging. Specific biomarkers with good sensitivity and specificity are therefore needed to predict clinical outcome and guide clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergantini, Laura, d’Alessandro, Miriana, Vietri, Lucia, Rana, Giuseppe Domenico, Cameli, Paolo, Acerra, Silvia, Sestini, Piersante, Bargagli, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674352/
https://www.ncbi.nlm.nih.gov/pubmed/33089426
http://dx.doi.org/10.1007/s12026-020-09158-0
_version_ 1783611486331994112
author Bergantini, Laura
d’Alessandro, Miriana
Vietri, Lucia
Rana, Giuseppe Domenico
Cameli, Paolo
Acerra, Silvia
Sestini, Piersante
Bargagli, Elena
author_facet Bergantini, Laura
d’Alessandro, Miriana
Vietri, Lucia
Rana, Giuseppe Domenico
Cameli, Paolo
Acerra, Silvia
Sestini, Piersante
Bargagli, Elena
author_sort Bergantini, Laura
collection PubMed
description Interstitial lung diseases (ILD) are a heterogeneous group of illnesses of known and unknown aetiology. Differential diagnosis among the three disorders is often challenging. Specific biomarkers with good sensitivity and specificity are therefore needed to predict clinical outcome and guide clinical decisions. The aim of this study was to investigate inflammatory/fibrotic biomarkers, to determine whether single mediators or panels of mediators could be useful to stratify patients into three distinct domains: sarcoidosis, idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (cHP). A total of 163 ILD patients monitored at Siena Referral Centre for Sarcoidosis and other Interstitial Lung Diseases were enrolled in the study. Clinical data, pulmonary function tests and biochemical analytes were retrospectively collected. SAA levels were detected by ELISA kit and Krebs von den Lungen 6 (KL-6) were measured by CLEIA method, for sarcoidosis, cHP and IPF patients. Multiple comparison analysis showed significant differences in C reactive protein (CRP), white blood cell count (WBC) and creatinine levels between the three groups. In the logistic regression model, KL-6, CRP and WBC showed areas under curves (AUC) 0.86, for sarcoidosis diagnosis. The logistic regression model KL-6 and SAA showed the best performance with an AUC 0.81 for discriminating IPF than cHP and sarcoidosis. For differential diagnosis of IPF and cHP, KL-6 and SAA were considered in the logistic regression model, showed an AUC 0.79. The combination of serum biomarkers proposed here offers insights into the pathobiology of ILDs. These panels of bioindicators will improve diagnostic accuracy and will be useful in the clinical management of ILDs.
format Online
Article
Text
id pubmed-7674352
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-76743522020-11-30 Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases Bergantini, Laura d’Alessandro, Miriana Vietri, Lucia Rana, Giuseppe Domenico Cameli, Paolo Acerra, Silvia Sestini, Piersante Bargagli, Elena Immunol Res Original Article Interstitial lung diseases (ILD) are a heterogeneous group of illnesses of known and unknown aetiology. Differential diagnosis among the three disorders is often challenging. Specific biomarkers with good sensitivity and specificity are therefore needed to predict clinical outcome and guide clinical decisions. The aim of this study was to investigate inflammatory/fibrotic biomarkers, to determine whether single mediators or panels of mediators could be useful to stratify patients into three distinct domains: sarcoidosis, idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (cHP). A total of 163 ILD patients monitored at Siena Referral Centre for Sarcoidosis and other Interstitial Lung Diseases were enrolled in the study. Clinical data, pulmonary function tests and biochemical analytes were retrospectively collected. SAA levels were detected by ELISA kit and Krebs von den Lungen 6 (KL-6) were measured by CLEIA method, for sarcoidosis, cHP and IPF patients. Multiple comparison analysis showed significant differences in C reactive protein (CRP), white blood cell count (WBC) and creatinine levels between the three groups. In the logistic regression model, KL-6, CRP and WBC showed areas under curves (AUC) 0.86, for sarcoidosis diagnosis. The logistic regression model KL-6 and SAA showed the best performance with an AUC 0.81 for discriminating IPF than cHP and sarcoidosis. For differential diagnosis of IPF and cHP, KL-6 and SAA were considered in the logistic regression model, showed an AUC 0.79. The combination of serum biomarkers proposed here offers insights into the pathobiology of ILDs. These panels of bioindicators will improve diagnostic accuracy and will be useful in the clinical management of ILDs. Springer US 2020-10-22 2020 /pmc/articles/PMC7674352/ /pubmed/33089426 http://dx.doi.org/10.1007/s12026-020-09158-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Bergantini, Laura
d’Alessandro, Miriana
Vietri, Lucia
Rana, Giuseppe Domenico
Cameli, Paolo
Acerra, Silvia
Sestini, Piersante
Bargagli, Elena
Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title_full Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title_fullStr Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title_full_unstemmed Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title_short Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
title_sort utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674352/
https://www.ncbi.nlm.nih.gov/pubmed/33089426
http://dx.doi.org/10.1007/s12026-020-09158-0
work_keys_str_mv AT bergantinilaura utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT dalessandromiriana utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT vietrilucia utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT ranagiuseppedomenico utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT camelipaolo utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT acerrasilvia utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT sestinipiersante utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases
AT bargaglielena utilityofserologicalbiomarkerpanelsfordiagnosticaccuracyofinterstitiallungdiseases